RECURSION PHARMACEUTICALS, INC. Research And Development Expense

Quick Answer

RECURSION PHARMACEUTICALS, INC. reported Research And Development Expense of $475.27 million for the year ending 2025.

  • RECURSION PHARMACEUTICALS, INC. showed an increase of +51.2% in Research And Development Expense from 2024 to 2025.
  • This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), RECURSION PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 937.5%.
  • Historical annual values: Fiscal year 2025: $475.27 million | Fiscal year 2024: $314.42 million | Fiscal year 2023: $241.23 million | Fiscal year 2022: $155.70 million | Fiscal year 2021: $135.27 million | Fiscal year 2020: $63.32 million | Fiscal year 2019: $45.81 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: